PL1915349T3 - Sposób wytwarzania czystej bezpostaciowej rozuwastatyny wapniowej - Google Patents

Sposób wytwarzania czystej bezpostaciowej rozuwastatyny wapniowej

Info

Publication number: PL1915349T3
Authority: PL; Poland
Prior art keywords: rosuvastatin calcium; pure amorphous; preparing pure; amorphous rosuvastatin; preparing
Prior art date: 2005-06-24

Application number

PL06754502T

Other languages

English (en)

Other versions

PL1915349T5 (pl

Inventor

Zdenko Casar

Marko Zlicar

Original Assignee

Lek Pharmaceuticals

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-06-24

Filing date

2006-06-22

Publication date

2016-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37440674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1915349(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-06-22 Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals

2016-05-31 Publication of PL1915349T3 publication Critical patent/PL1915349T3/pl

2019-02-28 Publication of PL1915349T5 publication Critical patent/PL1915349T5/pl

Links

238000004519 manufacturing process Methods 0.000 title 1
229960004796 rosuvastatin calcium Drugs 0.000 title 1
LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL06754502T 2005-06-24 2006-06-22 Sposób wytwarzania czystej bezpostaciowej rozuwastatyny wapniowej PL1915349T5 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SI200500187		2005-06-24
PCT/EP2006/006008 WO2006136408A2 (en)	2005-06-24	2006-06-22	Process for preparing pure amorphous rosuvastatin calcium
EP06754502.0A EP1915349B2 (en)	2005-06-24	2006-06-22	Process for preparing pure amorphous rosuvastatin calcium

Publications (2)

Publication Number	Publication Date
PL1915349T3 true PL1915349T3 (pl)	2016-05-31
PL1915349T5 PL1915349T5 (pl)	2019-02-28

Family

ID=37440674

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL06754502T PL1915349T5 (pl)	2005-06-24	2006-06-22	Sposób wytwarzania czystej bezpostaciowej rozuwastatyny wapniowej

Country Status (12)

Country	Link
US (1)	US8207333B2 (pl)
EP (1)	EP1915349B2 (pl)
JP (1)	JP5416403B2 (pl)
CN (1)	CN101203496B (pl)
AU (1)	AU2006261088B2 (pl)
CA (1)	CA2611920C (pl)
ES (1)	ES2564807T5 (pl)
HU (1)	HUE027012T2 (pl)
IL (1)	IL187578A0 (pl)
PL (1)	PL1915349T5 (pl)
SI (1)	SI1915349T1 (pl)
WO (1)	WO2006136408A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2870593B2 (ja)	1997-02-03	1999-03-17	日本電気株式会社	焦点誤差検出器
EP1562912A2 (en)	2003-08-28	2005-08-17	Teva Pharmaceutical Industries Limited	Process for preparation of rosuvastatin calcium
EP1601658A1 (en)	2003-11-24	2005-12-07	Teva Pharmaceutical Industries Limited	Crystalline ammonium salts of rosuvastatin
CN1894221B (zh)	2003-12-02	2012-08-08	特瓦制药工业有限公司	用于表征罗苏伐他汀的参照标准品
MX2007010138A (es)	2005-02-22	2007-09-27	Teva Pharma	Preparacion de rosuvastatina.
CN102807530B (zh) *	2005-06-24	2015-08-05	力奇制药公司	制备不含杂质的无定型罗苏伐他汀钙的方法
TW200800917A (en)	2005-08-16	2008-01-01	Teva Pharma	Crystalline rosuvastatin intermediate
KR20080060284A (ko)	2006-09-18	2008-07-01	테바 파마슈티컬 인더스트리즈 리미티드	결정질 로수바스타틴 칼슘
US8318933B2 (en) *	2006-10-31	2012-11-27	Aurobindo Pharma Ltd	Process for preparing rosuvastatin calcium
ATE553098T1 (de) *	2007-02-08	2012-04-15	Aurobindo Pharma Ltd	Verfahren zur herstellung von rosuvastatin- calcium
JP2010501643A (ja)	2007-07-12	2010-01-21	テバファーマシューティカルインダストリーズリミティド	薄膜蒸発及び化学的手法によるロスバスタチン中間体の精製
EP2298745B1 (en)	2008-05-27	2014-09-03	Changzhou Pharmaceutical Factory	Preparation method of rosuvastatin calcium and its intermediates
WO2010035284A2 (en) *	2008-09-26	2010-04-01	Matrix Laboratories Ltd	An improved process for the preparation of rosuvastatin calcium
EP2387566B1 (en) *	2009-01-14	2014-05-07	KRKA, tovarna zdravil, d.d., Novo mesto	Process for the preparation of rosuvastatin
EA021942B1 (ru) *	2009-01-15	2015-10-30	Эгиш Дьёдьсердьяр Зрт.	Способ изготовления солей розувастатина
WO2011021058A1 (en)	2009-08-17	2011-02-24	Aurobindo Pharma Limited	Process for the manufacture of rosuvastatin calcium using crystalline rosuvastatin ethyl ester
HU230987B1 (hu)	2010-11-29	2019-08-28	Egis Gyógyszergyár Nyrt.	Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
FR2970178B1 (fr)	2011-01-07	2014-06-20	Liliane Therese Jacquot	Promedicaments pour une delivrance specifique au niveau du foie et une meilleure tolerance
CN102070537B (zh) *	2011-01-28	2012-01-11	海南美大制药有限公司	一种瑞舒伐他汀钙化合物及其新制法
WO2013046222A2 (en) *	2011-08-10	2013-04-04	Glenmark Generics Limited	A process for the preparation of amorphous rosuvastatin calcium
CN103709107B (zh) *	2012-09-29	2016-04-20	安徽省庆云医药化工有限公司	瑞舒伐他汀甲酯的新晶型及其制备方法
CN104370827B (zh) *	2013-08-13	2016-09-07	天津汉瑞药业有限公司	瑞舒伐他汀钙化合物
EP3103878A4 (en) *	2014-02-06	2017-08-16	API Corporation	Rosuvastatin calcium and process for producing intermediate thereof
AU2015217221A1 (en)	2014-02-13	2016-08-11	Ligand Pharmaceuticals, Inc.	Prodrug compounds and their uses
AU2019207625A1 (en) *	2018-01-09	2020-07-30	Ligand Pharmaceuticals, Inc.	Acetal compounds and therapeutic uses thereof
CN108398501A (zh) *	2018-03-02	2018-08-14	海南通用三洋药业有限公司	一种检测瑞舒伐他汀钙有关物质的方法
CN108675931A (zh) *	2018-05-18	2018-10-19	合肥合源药业有限公司	一种低钡他汀钙及其制备方法
CN111170950A (zh) *	2020-01-16	2020-05-19	河南豫辰药业股份有限公司	一种瑞舒伐他汀钙盐的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2648897B2 (ja) *	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
GB9903472D0 (en)	1999-02-17	1999-04-07	Zeneca Ltd	Chemical process
GB0003305D0 (en) *	2000-02-15	2000-04-05	Zeneca Ltd	Pyrimidine derivatives
GB0218781D0 (en)	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
GB0312896D0 (en)	2003-06-05	2003-07-09	Astrazeneca Ab	Chemical process
EP1562912A2 (en)	2003-08-28	2005-08-17	Teva Pharmaceutical Industries Limited	Process for preparation of rosuvastatin calcium
US20070191318A1 (en) *	2003-10-22	2007-08-16	Yatendra Kumar	Process for the preparation of amorphous rosuvastatin calcium
WO2005054207A1 (en)	2003-12-04	2005-06-16	Glenmark Pharmaceuticals Limited	Process for the preparation of pyrimidine derivatives
WO2005077917A1 (en)	2004-01-19	2005-08-25	Ranbaxy Laboratories Limited	Amorphous salts of rosuvastatin
WO2006035277A2 (en) *	2004-09-27	2006-04-06	Ranbaxy Laboratories Limited	Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium

2006
- 2006-06-22 CN CN2006800226730A patent/CN101203496B/zh not_active Expired - Fee Related
- 2006-06-22 JP JP2008517414A patent/JP5416403B2/ja not_active Expired - Fee Related
- 2006-06-22 US US11/916,599 patent/US8207333B2/en not_active Expired - Fee Related
- 2006-06-22 PL PL06754502T patent/PL1915349T5/pl unknown
- 2006-06-22 HU HUE06754502A patent/HUE027012T2/en unknown
- 2006-06-22 ES ES06754502T patent/ES2564807T5/es active Active
- 2006-06-22 AU AU2006261088A patent/AU2006261088B2/en not_active Ceased
- 2006-06-22 SI SI200632034A patent/SI1915349T1/sl unknown
- 2006-06-22 WO PCT/EP2006/006008 patent/WO2006136408A2/en not_active Ceased
- 2006-06-22 CA CA2611920A patent/CA2611920C/en not_active Expired - Fee Related
- 2006-06-22 EP EP06754502.0A patent/EP1915349B2/en not_active Not-in-force
2007
- 2007-11-22 IL IL187578A patent/IL187578A0/en active IP Right Grant

Also Published As

Publication number	Publication date
SI1915349T1 (sl)	2016-05-31
PL1915349T5 (pl)	2019-02-28
CA2611920C (en)	2015-05-05
ES2564807T5 (es)	2019-02-26
CN101203496B (zh)	2011-04-20
EP1915349B1 (en)	2015-12-09
IL187578A0 (en)	2008-03-20
US8207333B2 (en)	2012-06-26
EP1915349A2 (en)	2008-04-30
EP1915349B2 (en)	2018-09-12
WO2006136408A2 (en)	2006-12-28
CA2611920A1 (en)	2006-12-28
AU2006261088B2 (en)	2012-11-08
ES2564807T3 (es)	2016-03-29
HUE027012T2 (en)	2016-10-28
CN101203496A (zh)	2008-06-18
AU2006261088A1 (en)	2006-12-28
JP2008543899A (ja)	2008-12-04
JP5416403B2 (ja)	2014-02-12
WO2006136408A3 (en)	2007-04-19
US20080188504A1 (en)	2008-08-07

Publication	Publication Date	Title
IL187578A0 (en)	2008-03-20	Process for preparing pure amorphous rosuvastatin calcium
IL187483A0 (en)	2008-02-09	Process for preparing amorphous rosuvastatin calcium free of impurities
ZA200704535B (en)	2008-11-26	Process for preparing rosuvastatin
PL1727795T3 (pl)	2012-06-29	Sposób wytwarzania soli wapniowej atorwastatyny w formie bezpostaciowej
SI1923359T1 (sl)	2016-04-29	Postopek za izdelavo vial
IL182474A0 (en)	2007-07-24	Process for forming amorphous atorvastatin
EP1828170A4 (en)	2009-11-11	PROCESS FOR PREPARING VORICONAZOLE
IL197327A0 (en)	2009-12-24	Crystalline rosuvastatin calcium
IL183239A0 (en)	2007-08-19	Process for preparing amorphous valsartan
IL209568A0 (en)	2011-01-31	Pyrimidine compound crystal or amorphous form and process for producing the same
IL184874A0 (en)	2007-12-03	Process for preparing protected amidines
IL185872A0 (en)	2008-01-06	Process for preparing levetiracetam
IL178001A0 (en)	2006-12-31	Process for preparing 5-methyl-2-furfural
TWI372145B (en)	2012-09-11	Process for preparing alkylanilides
EP1751123A4 (en)	2010-06-30	PROCESS FOR PREPARING IRBESARTAN
ZA200806049B (en)	2009-10-28	Cefdinir synthesis process
IL182211A0 (en)	2007-07-24	Process for preparing purine compounds
GB0614245D0 (en)	2006-08-30	Synthesis process
IL189574A0 (en)	2008-08-07	Process for preparing 1-substituted-5-acylimidazole compounds
IL178574A0 (en)	2007-02-11	Process for forming amorphous atorvastatin calcium
EP1856101A4 (en)	2009-10-21	PROCESS FOR PREPARING AMORPHENE SALTS
EP1907474A4 (en)	2010-09-15	PROCESS FOR PRODUCING A POLYOLEFIN
IL186460A0 (en)	2008-01-20	Process for preparing bicyclic compounds
IL183804A0 (en)	2007-09-20	Process for preparing substituted 2-alkoxycarbonyl-3-aminothiophenes
EP1870408A4 (en)	2009-07-22	A NEW METHOD FOR THE PRODUCTION OF RAMOSETRON OR ITS SALT